**Important Notice to Investors**

**SKK Ventures QP, LLC Series WG4 (the “Fund”)**

As more fully described in the offering documents of the Fund, the strategy of Series WG4 is to invest in the Series B Preferred Shares of Windgap Medical, Inc. (“Windgap”). As of August 1, 2019 the manager of the Fund, SKK Ventures QP Manager, LLC (the “Manager”), which is an affiliate of the Fund’s adviser, Shepherd Kaplan Krochuk, LLC (“SKK”), has entered a transaction with Windgap to purchase approximately $2.4 million of Series B Preferred Shares of Windgap (the “Stock”) under a “warehousing” arrangement on behalf of the Fund. Under this arrangement, the Fund will be purchasing shares from the Manager that the Manager purchased earlier in order to meet strategic needs of the Company and the Fund.

**The Manager’s Acquisition of the Stock**

SKK and the Manager determined that it was in the best interests of the Fund and the Company to purchase shares of the Company on or about August 1, 2019, but the Fund did not have sufficient investable capital at that time. To meet the investment timing goals of the Fund, the Manager acquired the Stock with capital borrowed from Provident Healthcare Capital, LLC (“PHC”). The Manager has pledged the Stock as collateral for that loan. Under the Stock Pledge Agreement between PHC and the Manager, the security interest in the Stock may be released by full or partial payment of the loan. The loan, the Stock, and the security interest were all in the name of the Manager, and the Fund did not take on any debt or other leverage as part of the transaction.

**The Anticipated Transfer of the Stock to the Fund**

SKK anticipates one or more closings involving the Fund and the Manager in which a) capital from new subscriptions in the Fund will be used by the Fund to purchase some or all of the Stock from the Manager; b) the Manager will use those proceeds to partially or fully repay the loan from PHC; c) PCH will release the security interest on the Stock to be transferred; d) the Manager will transfer all or a portion of the Stock to the Fund on the same terms and at the same price as though the Fund had bought the Stock from Windgap directly; and e) Windgap will be instructed to update its records and complete such documentation as required to provide the Fund the full interest and rights in the Stock as though the Fund had invested directly with Windgap.   
The Manager and/or SKK will bear all the expenses related to the loan from PHC, including the payment of any accrued interest. The Fund will still bear its ordinary fees payable to the Manager and/or SKK.

**Certain Conflicts of Interest related to this Notice**

SKK and the Manager had certain conflicts in arranging the transactions described in this notice. As described in the Private Placement Memorandum Supplement for the Fund, Timothy Krochuk, a Managing Member of SKK, has been appointed by the Fund as a director of Windgap. As a director, Mr. Krochuk has duties of care and loyalty to Windgap, which could potential conflict with his duties to the Fund. In addition, as a director, Mr. Krochuk has been provided stock options in Windgap, which may provide an incentive for him to take actions to improve the value of his options that could be inconsistent with those of the Fund. Nonetheless, in the context of the transactions described in this notice, SKK believes that Mr. Krochuk’s interests in helping further the strategic goals of Windgap are aligned with the interests of the Fund. The Manager and/or SKK have also agreed to bear the borrowing costs of warehousing the Stock in order to further mitigate any perceived conflict of interest.

In addition, as described in the Private Placement Memorandum Supplement for the Fund, PHC is related to Provident Healthcare Partners, LLC, a company with which SKK and another fund sponsored by SKK have additional business relationships and interests.

Acknowledged by the limited partner:

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_